Table 2.

KRAS wild-type cases by MSK-IMPACT (19 cases)

SamplesAlteration
1Intraductal tubulopapillary neoplasmFGFR2–MYOF fusion
2EBV poorly differentiated carcinomaFAT1 nonsense
3Adenocarcinoma with mucinous featuresNTRK3–ETV fusion
4Colloid carcinoma arising from IPMNGNAS R201C
5Colloid carcinomaGNAS R201H
6Pancreas adenocarcinomaMGA nonsense
7Pancreas adenocarcinomaBRCA2 loss (also germline)
8Pancreas adenocarcinomaTP53 mutant, RB1 loss
9Pancreas adenocarcinomaTP53 mutant, CDKN2A, MYC AMP
10Pancreas adenocarcinomaTP53 mutant, CDKN2A, SMAD4 loss, MYC AMP
11Pancreas adenocarcinomaERBB2 AMP, CDKN2A loss
12Pancreas adenocarcinomaAPC Missense
13Pancreas adenocarcinomaTP53 mutant, APC missense, NCOR1 amp
14Pancreas adenocarcinomaCCNE1 AMP
15Pancreas adenocarcinomaBRAF V600E, SMAD4 Loss
16Pancreas adenocarcinomaSMARCB1 loss
17Pancreas adenocarcinomaBCOR loss
18Pancreas adenocarcinomaROS1-SLC4A4 Fusion, ATM loss, ERBB2 AMP
19Pancreas adenocarcinomaTP53 mutant, SMAD4 loss, BRAF-JHDM1Dfusion